About Us Strategy & Mission Our Values Our People Our Board Our Collaborations Contact Our Programmes Overview Pipeline C. difficile Infection Enterobacteriaceae ESKAPE Programme Clinical Trials Stewardship Compassionate Use Our Science Discuva Platform Publications Investors Investor Centre Press Releases Financial Reports & Filings Email Alerts Events & Presentations Share Price Data Analyst Coverage Corporate Governance Shareholder Meetings Careers
SMT19969 has Good Activity Against Prevalent Clostridium difficile Ribotypes with Varying Antimicrobial Resistance SMT19969 has Good Activity Against Prevalent Clostridium difficile Ribotypes with Varying Antimicrobial Resistance September 20, 2015 By CKD Digital
SMT19969 has Good Activity Against Prevalent Clostridium difficile Ribotypes with Varying Antimicrobial Resistance
SMT19969 has Good Activity Against Prevalent Clostridium difficile Ribotypes with Varying Antimicrobial Resistance September 20, 2015 By CKD Digital